About our charity partners
Edinburgh Cancer Research Centre
The Cancer Research UK Edinburgh Centre brings together cancer scientists and clinicians from across the University of Edinburgh delivering outstanding cancer research. The co-located Edinburgh Cancer Centre provides cutting-edge oncological patient care to a quarter of the Scottish population.
Ovarian cancer is one of the research priority tumours for the Cancer Research UK Edinburgh Centre. The research is carried out by Professor Charlie Gourley in the Nicola Murray Centre for Ovarian Cancer Research. His team have provided national leadership on low grade serous ovarian cancer clinical trials and are now performing laboratory research to inform the next generation of low grade serous ovarian cancer clinical trials.
BC Cancer Foundation
The BC Cancer Foundation is the fundraising partner of BC Canada and the largest charitable funder of cancer research in British Columbia. With BC Canada Foundation's support, BC Cancer's world-leading ovarian cancer research (OVCARE) team is advancing prevention, diagnosis and treatment for all women facing gynecological cancers including low-grade serous ovarian cancer.
Over the past few years, an OVCARE research team, led by Dr. Mark Carey, has made significant progress in the search for better treatments for women facing low-grade serous ovarian cancer. They are the largest and most experienced low-grade serous research group in Canada.
GRACI Foundation (Gynaecological Cancer Research and Clinical Innovation)
The Graci Foundation was established to improve outcomes for women suffering from a gynaecological cancer by supporting New Zealand based research. The trustees know that research is the key to progress; and are passionate to see women with low-grade serous ovarian cancer benefit from the latest advancements in the field.
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center in Houston is one of the world's most respected centers focused on cancer patient care, research, education and prevention. It was named the nation's No. 1 hospital for cancer care in U.S. News & World Report’s 2018 rankings.
It is one of the nation's original three comprehensive cancer centers designated by the National Cancer Institute. Since 1944, more than 1.2 million patients have sought out MD Anderson’s expertise.
The institution pioneered a multidisciplinary approach to research-driven care. Their researchers include Dr David Gershenson who is widely considered to be the world expert on low-grade serous ovarian cancer. Research carried out by the MD Anderson Cancer Center has helped form many of the current treatment recommendations for women with low-grade serous ovarian cancer.